Filovirus VP24 Proteins Differentially Regulate RIG-I and MDA5-Dependent Type I and III Interferon Promoter Activation.
Cell Line, Tumor
DEAD Box Protein 58
/ genetics
Filoviridae
/ genetics
Gene Expression Regulation
/ immunology
HEK293 Cells
Humans
Interferon Type I
/ genetics
Interferon-Induced Helicase, IFIH1
/ genetics
Interferons
/ genetics
Interleukins
/ genetics
Promoter Regions, Genetic
/ immunology
Receptors, Immunologic
/ genetics
Viral Proteins
/ genetics
MDA5 pathway
RIG-I pathway
VP24
ebolavirus
filovirus
innate immunity
type I interferon
type III interferon
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
04
2021
accepted:
14
12
2021
entrez:
24
1
2022
pubmed:
25
1
2022
medline:
24
2
2022
Statut:
epublish
Résumé
Filovirus family consists of highly pathogenic viruses that have caused fatal outbreaks especially in many African countries. Previously, research focus has been on Ebola, Sudan and Marburg viruses leaving other filoviruses less well studied. Filoviruses, in general, pose a significant global threat since they are highly virulent and potentially transmissible between humans causing sporadic infections and local or widespread epidemics. Filoviruses have the ability to downregulate innate immunity, and especially viral protein 24 (VP24), VP35 and VP40 have variably been shown to interfere with interferon (IFN) gene expression and signaling. Here we systematically analyzed the ability of VP24 proteins of nine filovirus family members to interfere with retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated antigen 5 (MDA5) induced IFN-β and IFN-λ1 promoter activation. All VP24 proteins were localized both in the cell cytoplasm and nucleus in variable amounts. VP24 proteins of Zaire and Sudan ebolaviruses, Lloviu, Taï Forest, Reston, Marburg and Bundibugyo viruses (EBOV, SUDV, LLOV, TAFV, RESTV, MARV and BDBV, respectively) were found to inhibit both RIG-I and MDA5 stimulated IFN-β and IFN-λ1 promoter activation. The inhibition takes place downstream of interferon regulatory factor 3 phosphorylation suggesting the inhibition to occur in the nucleus. VP24 proteins of Mengla (MLAV) or Bombali viruses (BOMV) did not inhibit IFN-β or IFN-λ1 promoter activation. Six ebolavirus VP24s and Lloviu VP24 bound tightly, whereas MARV and MLAV VP24s bound weakly, to importin α5, the subtype that regulates the nuclear import of STAT complexes. MARV and MLAV VP24 binding to importin α5 was very weak. Our data provides new information on the innate immune inhibitory mechanisms of filovirus VP24 proteins, which may contribute to the pathogenesis of filovirus infections.
Identifiants
pubmed: 35069519
doi: 10.3389/fimmu.2021.694105
pmc: PMC8767557
doi:
Substances chimiques
interferon-lambda, human
0
Interferon Type I
0
Interleukins
0
Receptors, Immunologic
0
Viral Proteins
0
Interferons
9008-11-1
RIGI protein, human
EC 3.6.1.-
IFIH1 protein, human
EC 3.6.1.-
DEAD Box Protein 58
EC 3.6.4.13
Interferon-Induced Helicase, IFIH1
EC 3.6.4.13
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
694105Informations de copyright
Copyright © 2022 He, Khan, Huttunen, Kolehmainen, Melén, Maljanen, Qu, Jiang, Kakkola and Julkunen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Immunol. 2007 Sep 15;179(6):3434-42
pubmed: 17785777
Arch Virol Suppl. 2008;20:13-360
pubmed: 18637412
Nature. 2018 Apr;556(7700):197-202
pubmed: 29618816
Viruses. 2015 Sep 29;7(10):5172-90
pubmed: 26426036
Cell Host Microbe. 2013 Jul 17;14(1):74-84
pubmed: 23870315
J Virol. 2020 Jun 16;94(13):
pubmed: 32295912
Cell Host Microbe. 2014 Aug 13;16(2):187-200
pubmed: 25121748
J Virol. 2006 Jun;80(11):5156-67
pubmed: 16698996
Arch Virol. 2016 Aug;161(8):2351-60
pubmed: 27216929
Front Immunol. 2019 Jul 17;10:1586
pubmed: 31379819
Curr Opin Virol. 2019 Apr;35:42-56
pubmed: 31003196
Mol Cell Biol. 1998 May;18(5):2986-96
pubmed: 9566918
Virol J. 2006 Sep 01;3:66
pubmed: 16945160
Virology. 1985 Nov;147(1):169-76
pubmed: 4060597
Methods. 2020 Nov 1;183:21-29
pubmed: 31682923
J Gen Virol. 2008 Jan;89(Pt 1):1-47
pubmed: 18089727
J Virol. 2012 Mar;86(6):2900-10
pubmed: 22258243
J Virol. 2015 Dec;89(23):12014-25
pubmed: 26378160
Nat Rev Microbiol. 2015 Nov;13(11):663-76
pubmed: 26439085
J Microbiol Methods. 2008 Oct;75(2):318-24
pubmed: 18674572
Virology. 2017 Jan 15;501:147-165
pubmed: 27930961
FEMS Microbiol Rev. 2016 Jul;40(4):494-519
pubmed: 27268907
J Virol. 2009 Apr;83(7):3069-77
pubmed: 19153231
J Biol Chem. 2002 Aug 16;277(33):30072-8
pubmed: 12048190
J Immunol. 2011 Aug 15;187(4):1713-21
pubmed: 21742966
Viruses. 2019 Nov 04;11(11):
pubmed: 31690057
J Biol Chem. 2003 Jul 25;278(30):28193-200
pubmed: 12740372
Elife. 2016 Mar 24;5:e11275
pubmed: 27011352
Nat Immunol. 2004 Jul;5(7):730-7
pubmed: 15208624
Virology. 2015 Nov;485:145-52
pubmed: 26255028
Arch Virol. 2010 Dec;155(12):2083-103
pubmed: 21046175
J Leukoc Biol. 2015 Feb;97(2):307-20
pubmed: 25473098
Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):637-42
pubmed: 11805321
Virology. 2017 Sep;509:23-34
pubmed: 28595092
Curr Opin Virol. 2014 Jun;6:40-6
pubmed: 24713352
J Virol. 2014 Nov;88(21):12500-10
pubmed: 25142601
J Biol Chem. 2006 Jan 27;281(4):2095-103
pubmed: 16306043
PLoS Pathog. 2010 Jan 15;6(1):e1000721
pubmed: 20084112
Virology. 2015 May;479-480:122-30
pubmed: 25843618